Zomedica Expands TRUFORMA Platform with Equine Progesterone Assay Launch

Zomedica Corp. has unveiled a new addition to its TRUFORMA platform with the introduction of the Equine Progesterone Assay. This advancement targets reproductive health in the equine industry, aiming to enhance breeding programs and pregnancy monitoring. The Progesterone assay expands the platform's scope from endocrine diagnostics to reproductive applications, addressing a substantial market need among horse owners, breeders, and veterinarians.

The equine reproduction market, especially underserved in point-of-care diagnostics, represents a significant opportunity with an estimated worth rising from $485 million in 2024 to $845 million by 2031. This growth underscores the increasing demand for tools that optimize reproductive efficiency and lower costs. Zomedica's new assay offers immediate, in-clinic results, enhancing decision-making and improving breeding outcomes.